257 related articles for article (PubMed ID: 21386782)
1. Dosimetry in nuclear medicine therapy: what are the specifics in image quantification for dosimetry?
Bardiès M; Buvat I
Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):5-20. PubMed ID: 21386782
[No Abstract] [Full Text] [Related]
2. [Nuclear medicine in oncotherapy].
Pávics L; Besenyi Z
Magy Onkol; 2015 Sep; 59(3):193-7. PubMed ID: 26339908
[TBL] [Abstract][Full Text] [Related]
3. [Nuclear medicine in oncology: new diagnostic and therapeutic methods].
Maublant J; Lumbroso J; Cachin F; Raoul JL; Syrota A; Vuillez JP
Bull Cancer; 2001 Jan; 88(1):35-44. PubMed ID: 11182651
[No Abstract] [Full Text] [Related]
4. Dosimetry in nuclear medicine therapy.
Chiesa C; Lassmann M
Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):2-4. PubMed ID: 21386781
[No Abstract] [Full Text] [Related]
5. Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray".
Flux G; Bardies M; Chiesa C; Monsieurs M; Savolainen S; Strand SE; Lassmann M
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1699-700. PubMed ID: 17565497
[No Abstract] [Full Text] [Related]
6. Clinical applications of dosimetry for mIBG therapy.
Flux GD; Chittenden SJ; Saran F; Gaze MN
Q J Nucl Med Mol Imaging; 2011 Apr; 55(2):116-25. PubMed ID: 21386786
[TBL] [Abstract][Full Text] [Related]
7. Quantitative imaging of (124)I with PET/ CT in pretherapy lesion dosimetry. Effects impairing image quantification and their corrections.
Jentzen W; Freudenberg L; Bockisch A
Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):21-43. PubMed ID: 21386783
[TBL] [Abstract][Full Text] [Related]
8. Intraarterial 131I-MIBG therapy of neuroendocrine tumors with liver metastases.
Popp M; Strumpf A; Zöphel K; Stroszczynski C; Kotzerke J
Nuklearmedizin; 2010; 49(1):N2-3. PubMed ID: 20336828
[No Abstract] [Full Text] [Related]
9. [Therapeutic advances of nuclear medicine in oncology].
Valdés Olmos RA; Hoefnagel CA; Bais E; Boot H; Taal B; de Kraker J; Vote PA
Rev Esp Med Nucl; 2001 Dec; 20(7):547-57. PubMed ID: 11709141
[TBL] [Abstract][Full Text] [Related]
10. Spatial dose mapping for individualizing radioiodine treatment.
Lassmann M; Hänscheid H
J Nucl Med; 2007 Jan; 48(1):2-4. PubMed ID: 17204691
[No Abstract] [Full Text] [Related]
11. Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray".
Brans B; Bodei L; Giammarile F; Linden O; Luster M; Oyen WJG; Tennvall J
Eur J Nucl Med Mol Imaging; 2007 May; 34(5):772-786. PubMed ID: 17268773
[TBL] [Abstract][Full Text] [Related]
12. Dosimetry and treatment planning in radioimmunotherapy.
Leichner PK; Yang NC; Wessels BW; Hawkins WG; Order SE; Klein JL
Front Radiat Ther Oncol; 1990; 24():109-20; discussion 121-2. PubMed ID: 2160407
[No Abstract] [Full Text] [Related]
13. Use of 131 I-MIBG therapy in MIBG-positive metastatic medullary thyroid carcinoma.
Maiza JC; Grunenwald S; Otal P; Vezzosi D; Bennet A; Caron P
Thyroid; 2012 Jun; 22(6):654-5. PubMed ID: 22568397
[No Abstract] [Full Text] [Related]
14. (90)Y-PET/CT Imaging Quantification for Dosimetry in Peptide Receptor Radionuclide Therapy: Analysis and Corrections of the Impairing Factors.
Fabbri C; Bartolomei M; Mattone V; Casi M; De Lauro F; Bartolini N; Gentili G; Amadori S; Agostini M; Sarti G
Cancer Biother Radiopharm; 2015 Jun; 30(5):200-10. PubMed ID: 25860616
[TBL] [Abstract][Full Text] [Related]
15. Dosimetry in nuclear medicine therapy: radiobiology application and results.
Strigari L; Benassi M; Chiesa C; Cremonesi M; Bodei L; D'Andrea M
Q J Nucl Med Mol Imaging; 2011 Apr; 55(2):205-21. PubMed ID: 21386791
[TBL] [Abstract][Full Text] [Related]
16. From imaging to dosimetry and biological effects.
Konijnenberg M
Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):44-56. PubMed ID: 21386784
[TBL] [Abstract][Full Text] [Related]
17. 131I dosimetry and thyroid stunning.
Gerard SK; Park HM
J Nucl Med; 2003 Dec; 44(12):2039-40; author reply 2040. PubMed ID: 14660731
[No Abstract] [Full Text] [Related]
18. Blood and bone marrow dosimetry in radioiodine therapy of thyroid cancer.
Sgouros G
J Nucl Med; 2005 May; 46(5):899-900; author reply 901. PubMed ID: 15872367
[No Abstract] [Full Text] [Related]
19. Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies.
Lopci E; Chiti A; Castellani MR; Pepe G; Antunovic L; Fanti S; Bombardieri E
Eur J Nucl Med Mol Imaging; 2011 May; 38 Suppl 1():S28-40. PubMed ID: 21484381
[TBL] [Abstract][Full Text] [Related]
20. Nuclear medicine applications for neuroendocrine tumors.
Chatal JF; Le Bodic MF; Kraeber-Bodéré F; Rousseau C; Resche I
World J Surg; 2000 Nov; 24(11):1285-9. PubMed ID: 11038195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
